The fourth quarter was not perfect for Roche (OTCQX:RHHBY),
but it was no worse than “good enough” and assuming management is
applying their typical caution with early guidance, 2020 is shaping up
as a good year. Although I have few if any real concerns with the pharma
business, the diagnostics business continues to look rather weak and is
an area that needs to be addressed.
Roche shares have risen another 10% since my last update,
but I’m still bullish on balance. The prospective returns aren’t what
I’d call superior, but I think the risk-adjusted return is still
attractive. On balance, I think Roche remains a good buy-and-hold for
investors who want pharma exposure, and particularly the kind where
management execution (on the pharma side, at least) is not an issue.
Continue here:
Roche Still Going Strong, As Pipeline Productivity Fuels Pharma Growth
No comments:
Post a Comment